from Breakingviews:

Abbott eases its M&A risk with $4.3 bln asset sale

September 19, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bristol-Myers suffers $21 bln self-inflicted wound

August 5, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Fintech: bigger and dicier for insurers than banks

July 13, 2016

The insurance industry is ripe for technological disruption, but the results may be dicey. Some areas of banking services, notably payments, have been relentlessly targeted by start-up companies since the financial crisis. But nine in 10 insurance executives polled by consultant PwC reckon at least part of their business is at risk over the next five years – a greater proportion than in any other area of finance.

from Breakingviews:

J&J’s corpulence defense weighs heavy

June 2, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

From Allergan to Zoetis: new drug M&A perspectives

May 10, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pfizer mulls actually having an M&A strategy

May 5, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Stupid names can’t hurt good companies

May 5, 2016

The author is a Reuters Breakingviews columnist.  The opinions expressed are his own.

from Breakingviews:

Medical firms’ $18 bln merger lacks clear logic

May 3, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Abbott’s $25 bln buy inspires little investor hope

April 28, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Valeant plays chicken with death spiral

March 15, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.